Overview

A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804

Status:
Completed
Trial end date:
2020-11-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to select a suitable dose of BPS804 by measuring the strength/quality of bone using a special type of CT scanner. Participants will be treated for 12 months and followed up for a further 12 months.
Phase:
Phase 2
Details
Lead Sponsor:
Mereo BioPharma
Ultragenyx Pharmaceutical Inc
Collaborator:
ICON Clinical Research